Our work, therefore, not only characterized a potent small molecular PD‐1 inhibitor of substantial possibility to benefit cancer patients immediately (for it is an FDA‐approved drug), but presents a novel strategy to develop PD‐1 inhibitors. Here, PDCD1 is linked to cancer.